A phase I/II study of CR011-vcMMAE in subjects with unresectable stage III or stage IV melanoma.

Trial Profile

A phase I/II study of CR011-vcMMAE in subjects with unresectable stage III or stage IV melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2015

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors CuraGen Corporation
  • Most Recent Events

    • 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2010 Results will be presented at ASCO 2010 (Abstract Control Number: 51525; Permanent Abstract ID: 8525), according to a Celldex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top